静脉注射帕拉米韦与口服奥司他韦治疗儿童流感的疗效和安全性：荟萃分析

IF 1.6 Q4 INFECTIOUS DISEASES Journal of clinical virology plus Pub Date : 2024-04-10 DOI:10.1016/j.jcvp.2024.100179

Jie Yuan , Shuhua An , Zhongfu Zhang

{"title":"静脉注射帕拉米韦与口服奥司他韦治疗儿童流感的疗效和安全性：荟萃分析","authors":"Jie Yuan , Shuhua An , Zhongfu Zhang","doi":"10.1016/j.jcvp.2024.100179","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the efficacy and safety of intravenous peramivir compared to oral oseltamivir for pediatric influenza by a method of meta-analysis.</p></div><div><h3>Methods</h3><p>Clinical trials involving intravenous peramivir versus oral oseltamivir therapy in children with influenza were searched from six databases until July 2023. Data were processed using Stata 15.0 software.</p></div><div><h3>Results</h3><p>Seven published articles were identified in this review. The combined results exhibited that the clinical effective rate in the peramivir group (76.09 %) was higher than that in the oseltamivir group (58.85 %) (RR= 1.12, 95 %CI: 1.01∼1.24, <em>P</em> = 0.038). The incidence of adverse reactions in the peramivir group (13.31 %) was lower than that in the oseltamivir group (17.34 %) (RR= 0.77, 95 %CI: 0.61–0.96, <em>P</em> = 0.023). Compared with the oseltamivir group, the peramivir group had lower recovery time of body temperature (WMD= -19.81, 95 %CI: -27.58∼-12.04, <em>P</em> < 0.001).</p></div><div><h3>Conclusion</h3><p>Compared with oral oseltamivir, intravenous peramivir has better efficacy and higher safety for pediatric influenza.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 2","pages":"Article 100179"},"PeriodicalIF":1.6000,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000048/pdfft?md5=3e38732d6d7310f107900a33973c9f81&pid=1-s2.0-S2667038024000048-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of intravenous peramivir versus oral oseltamivir in the treatment of influenza in children: A meta-analysis\",\"authors\":\"Jie Yuan , Shuhua An , Zhongfu Zhang\",\"doi\":\"10.1016/j.jcvp.2024.100179\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To investigate the efficacy and safety of intravenous peramivir compared to oral oseltamivir for pediatric influenza by a method of meta-analysis.</p></div><div><h3>Methods</h3><p>Clinical trials involving intravenous peramivir versus oral oseltamivir therapy in children with influenza were searched from six databases until July 2023. Data were processed using Stata 15.0 software.</p></div><div><h3>Results</h3><p>Seven published articles were identified in this review. The combined results exhibited that the clinical effective rate in the peramivir group (76.09 %) was higher than that in the oseltamivir group (58.85 %) (RR= 1.12, 95 %CI: 1.01∼1.24, <em>P</em> = 0.038). The incidence of adverse reactions in the peramivir group (13.31 %) was lower than that in the oseltamivir group (17.34 %) (RR= 0.77, 95 %CI: 0.61–0.96, <em>P</em> = 0.023). Compared with the oseltamivir group, the peramivir group had lower recovery time of body temperature (WMD= -19.81, 95 %CI: -27.58∼-12.04, <em>P</em> < 0.001).</p></div><div><h3>Conclusion</h3><p>Compared with oral oseltamivir, intravenous peramivir has better efficacy and higher safety for pediatric influenza.</p></div>\",\"PeriodicalId\":73673,\"journal\":{\"name\":\"Journal of clinical virology plus\",\"volume\":\"4 2\",\"pages\":\"Article 100179\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2667038024000048/pdfft?md5=3e38732d6d7310f107900a33973c9f81&pid=1-s2.0-S2667038024000048-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical virology plus\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667038024000048\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical virology plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667038024000048","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

目的通过荟萃分析法研究静脉注射培拉米韦与口服奥司他韦治疗小儿流感的疗效和安全性比较。结果本综述共发现七篇已发表的文章。综合结果显示，培拉米韦组的临床有效率（76.09%）高于奥司他韦组（58.85%）（RR= 1.12, 95 %CI: 1.01∼1.24, P = 0.038）。帕拉米韦组的不良反应发生率（13.31%）低于奥司他韦组（17.34%）（RR= 0.77，95 %CI：0.61-0.96，P = 0.023）。与口服奥司他韦组相比，静脉注射培拉米韦组的体温恢复时间更短（WMD= -19.81，95 %CI：-27.58∼-12.04，P < 0.001）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Efficacy and safety of intravenous peramivir versus oral oseltamivir in the treatment of influenza in children: A meta-analysis

Objective

To investigate the efficacy and safety of intravenous peramivir compared to oral oseltamivir for pediatric influenza by a method of meta-analysis.

Methods

Clinical trials involving intravenous peramivir versus oral oseltamivir therapy in children with influenza were searched from six databases until July 2023. Data were processed using Stata 15.0 software.

Results

Seven published articles were identified in this review. The combined results exhibited that the clinical effective rate in the peramivir group (76.09 %) was higher than that in the oseltamivir group (58.85 %) (RR= 1.12, 95 %CI: 1.01∼1.24, P = 0.038). The incidence of adverse reactions in the peramivir group (13.31 %) was lower than that in the oseltamivir group (17.34 %) (RR= 0.77, 95 %CI: 0.61–0.96, P = 0.023). Compared with the oseltamivir group, the peramivir group had lower recovery time of body temperature (WMD= -19.81, 95 %CI: -27.58∼-12.04, P < 0.001).